266 related articles for article (PubMed ID: 33155000)
1. Issues affecting nanomedicines on the way from the bench to the market.
Longo JPF; Mussi S; Azevedo RB; Muehlmann LA
J Mater Chem B; 2020 Dec; 8(47):10681-10685. PubMed ID: 33155000
[TBL] [Abstract][Full Text] [Related]
2. Nanomedical engineering: shaping future nanomedicines.
Luo D; Carter KA; Lovell JF
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(2):169-88. PubMed ID: 25377691
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine: is it lost in translation?
Greish K; Mathur A; Bakhiet M; Taurin S
Ther Deliv; 2018 Mar; 9(4):269-285. PubMed ID: 29495928
[TBL] [Abstract][Full Text] [Related]
4. Preclinical hazard evaluation strategy for nanomedicines.
Siegrist S; Cörek E; Detampel P; Sandström J; Wick P; Huwyler J
Nanotoxicology; 2019 Feb; 13(1):73-99. PubMed ID: 30182784
[TBL] [Abstract][Full Text] [Related]
5. Challenges in nanomedicine clinical translation.
Metselaar JM; Lammers T
Drug Deliv Transl Res; 2020 Jun; 10(3):721-725. PubMed ID: 32166632
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine.
Jang SF; Liu WH; Song WS; Chiang KL; Ma HI; Kao CL; Chen MT
Int J Mol Sci; 2014 Mar; 15(3):3904-25. PubMed ID: 24599081
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicines accessible in the market for clinical interventions.
Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
[TBL] [Abstract][Full Text] [Related]
8. How has nanomedical innovation contributed to the COVID-19 vaccine development?
Figueiró Longo JP; Muehlmann LA
Nanomedicine (Lond); 2021 Jun; 16(14):1179-1181. PubMed ID: 33973802
[No Abstract] [Full Text] [Related]
9. Specificity of pharmacokinetic modeling of nanomedicines.
Lebreton V; Legeay S; Saulnier P; Lagarce F
Drug Discov Today; 2021 Oct; 26(10):2259-2268. PubMed ID: 33892140
[TBL] [Abstract][Full Text] [Related]
10. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
[TBL] [Abstract][Full Text] [Related]
11. Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines.
Rösslein M; Liptrott NJ; Owen A; Boisseau P; Wick P; Herrmann IK
Nanotoxicology; 2017 Mar; 11(2):147-149. PubMed ID: 28055261
[TBL] [Abstract][Full Text] [Related]
12. Nanotechnology and nanomedicine: going small means aiming big.
Teli MK; Mutalik S; Rajanikant GK
Curr Pharm Des; 2010 Jun; 16(16):1882-92. PubMed ID: 20222866
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological research and pluripotent stem cells: from the innovative experimental paradigm to the successful clinical trial].
Baghdoyan S; Bassez G; Audureau E; Peschanski M
Med Sci (Paris); 2019 Jan; 35(1):26-29. PubMed ID: 30672450
[No Abstract] [Full Text] [Related]
14. Have nanomedicines progressed as much as we'd hoped for in drug discovery and development?
Sarmento B
Expert Opin Drug Discov; 2019 Aug; 14(8):723-725. PubMed ID: 31161834
[No Abstract] [Full Text] [Related]
15. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.
Farjadian F; Ghasemi A; Gohari O; Roointan A; Karimi M; Hamblin MR
Nanomedicine (Lond); 2019 Jan; 14(1):93-126. PubMed ID: 30451076
[TBL] [Abstract][Full Text] [Related]
16. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
17. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
18. Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines.
Moghimi SM; Andresen TL
Mol Immunol; 2009 May; 46(8-9):1571-2. PubMed ID: 19286261
[TBL] [Abstract][Full Text] [Related]
19. Mapping of the available standards against the regulatory needs for nanomedicines.
Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
[TBL] [Abstract][Full Text] [Related]
20. Recent developments of nanoparticle-delivered dosage forms for buccal delivery.
Tran PHL; Duan W; Tran TTD
Int J Pharm; 2019 Nov; 571():118697. PubMed ID: 31526839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
